Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops
Launched by CALM WATER THERAPEUTICS LLC · Dec 20, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
In this study CWT-f-002 lubricant eye drop is being evaluated in subjects with dry eye. This OTC eye drop has previously shown promising results in multiple preclinical and clinical settings. The active comparator for this study is Systane (R). Ingredient lists as follows. CWT-f-002: Active Ingredients are glycerin 0.7% and polyethylene glycol 400 0.4%. Inactive ingredients are mannitol, polylysine-graft-polyethylene glycol, sterile water for injection, and sodium phosphate buffer. Systane: Active ingredients are polyethylene glycol 400 0.4% and propylene glycol 0.3%. Inactive ingredients a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be at least 18 years of age
- • Have a reported history of dry eye for at least 6 months
- • Have a Tear Film Breakup Time (TFBUT) measurement of \>1 and \<7 seconds at Visit 1
- Exclusion Criteria:
- • Known contraindications or sensitivities to the use of the study treatment or any of its components
- • Have a clinically significant slit lamp finding at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters
- • Have a condition (ocular or systemic) that the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the trial
Trial Officials
Paul Gomes, MS
Study Director
Andover Research Eye Institute
About Calm Water Therapeutics Llc
Calm Water Therapeutics LLC is a pioneering clinical trial sponsor dedicated to advancing innovative therapeutic solutions for mental health and neurological disorders. Committed to rigorous scientific research and ethical standards, the company collaborates with leading researchers and healthcare professionals to develop and evaluate novel treatment modalities. With a focus on enhancing patient outcomes and improving quality of life, Calm Water Therapeutics leverages cutting-edge methodologies and robust clinical trial frameworks to bring transformative therapies to market. Their mission is to navigate the complexities of healthcare, fostering a calm and supportive environment for patients and stakeholders alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Andover, Massachusetts, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials